Search filters

Kuros Biosciences AG completes rights offering and share placement

Kuros Biosciences (SIX: KURN) completes a rights offering and share placement in which a total of 6,405,022 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00...

Public Offer of BFW Holding AG for BFW Liegenschaften AG

On November 29, 2019 BFW Holding AG published a friendly public offer for the SIX listed A shares of BFW Liegenschaften AG (going private). VISCHER (partners Felix W. Egli and Adrian Dörig as well as associates Sebastian Flückiger...

BACHEM completes Capital Increase

VISCHER advises on the capital increase of BACHEM HOLDING AG as transaction counsel. As a result of the capital increase, in which 400'000 new shares were issued, BACHEM (SIX: BANB) received gross proceeds of CHF 48 million, which...

Warteck Invest completes Capital Increase

VISCHER advises on the capital increase of Warteck Invest AG as transaction counsel. Warteck Invest is one of the oldest real estate companies listed on the SIX Swiss Exchange and is focusing on residential and business properties...

Kuros Biosciences enters convertible bond agreement

Kuros Biosciences AG (Kuros) entered into a convertible bond financing agreement with Nice & Green SA for up to a maximum of CHF 5 million. The facility is provided by Nice & Green SA (N&G), a private Swiss company which...

wefox Group raises USD 125 million in B round

wefox Group, the Berlin-based insurtech firm with headquarter in Zurich has successfully raised USD 125 million for its series B round. The USD 125 million investment is the largest series B round for an insurtech company...

USD 100 million debt financing by Hercules Capital to Urovant Sciences

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has entered into a debt financing agreement with Hercules Capital,...

Arvelle Therapeutics raises USD 180 million in Series A financing

A global syndicate of investors led by LSP and including NovaQuest, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners supported new company Arvelle Therapeutics with a USD 180 million financing to acquire the...

Success in OTC-derivatives dispute before the Federal Supreme Court

On 16 September 2016, the District Court of Zurich fully dismissed the objection by the two single largest third-party creditors against the schedule of claims of Lehman Brothers Finance AG in liquidation. The Supreme Court of the...

Kuros Biosciences AG completes rights offering and share placement

Kuros Biosciences (SIX: KURN) completes a rights offering and share placement in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00...

You are currently offline. Some pages or content may fail to load.